

Ref: EPL/CS/SE/0004/2026

Date: January 22, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation for Earnings Call - Q3 FY26

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that the **Earnings Call for Investors/ Analysts** will be held on **Wednesday, February 04, 2026** at **04:00 p.m. (IST)** to discuss the Company's Unaudited Financial Results (Standalone And Consolidated) and performance for the quarter and nine months ended December 31, 2025.

The details of the aforesaid earnings call for Investors/ Analysts is enclosed.

The transcript and the audio recording of the Earnings Call will be made available on the Company's website i.e. www.emcure.com and will be intimated accordingly.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Tajuddin Shaikh
Chief Financial Officer

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251



Emcure Pharmaceuticals Ltd. Q3FY26 Results Earnings Call

Date: **Wednesday, Feb 04, 2026**

Time: **4:00 pm – 5:00 pm IST**

Dial – in Numbers:

Universal Access Number:

+91 22 6280 1220

+91 22 7115 8122

Hong Kong: 800 964 448

Singapore: 800 101 2045

UK: 080 8101 1573

USA: 186 674 62133

[To pre-register online, please click here](#)

For any clarification, please contact:

E-mail: investor.relations@emcure.com